core symptoms of autism in children, in what developers say could be a world first if successful. The Monash Health study will recruit 150 Victorian children with autism spectrum disorder, who will receive either a placebo or twice-daily drops of the CBDA‑rich oil, which contains only low doses of THC. Earlier pilot and Phase 2 trials led by Professor Michael Fahey at Monash Children’s Hospital found improvements in anxiety, mood and cognitive engagement in about 84 per cent of children within eight weeks, giving families cautious hope where few targeted treatments exist. Neurotech International says positive results could pave the way for one of the first approved medicines aimed at autism’s core symptoms in children worldwide. Read the original report in the Herald Sun here.